• Reata's Kidney Drug Hits Goals of Key Study, Paves Way for FDA Filing

    1 month ago - By Xconomy

    About half of all patients with the most severe form of Alport syndrome, a rare, genetic type of chronic kidney disease, will need dialysis or a transplant by age 25. On Monday, Reata Pharmaceuticals announced that its investigational drug for those with Alport syndrome, bardoxolone methyl , met the main goal of a Phase 3 clinical trial. After 48 weeks of treatment, patients in the study who received bard saw their kidney function-as measured by a blood test that estimates how much blood passes through filters in the kidneys each minute-improve compared to a placebo. Data from the...
    Read more ...